Clinical Trial Update: Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years [Phase 3]

View source ↗

Summary

Immunobridging study in Phase 3 evaluating a 9-valent HPV vaccine in Chinese females aged 9 to 19; trial status is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Intraepithelial Neoplasia
• Cervical Cancer
• Cervical Intraepithelial Neoplasia 1
• Cervical Intraepithelial Neoplasia 2
• Cervical Intraepithelial Neoplasia 3
• Genital Warts
• Human Papillomavirus Infection
• Vaginal Cancer
• Vaginal Intraepithelial Neoplasia 1
• Vaginal Intraepithelial Neoplasia 2
• Vaginal Intraepithelial Neoplasia 3
• Vulvar Cancer
• Vulvar Intraepithelial Neoplasia 1
• Vulvar Intraepithelial Neoplasia 2
• Vulvar Intraepithelial Neoplasia 3

Drugs mentioned

• 9-valent Human Papillomavirus Recombinant Vaccine (HPV9 vaccine)

Snippet

Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Conditions: HPV Infections, Cervical Cancer | Phase 3 | Status: RECRUITING